@article {7566,
	title = {International Myeloma Working Group recommendations for global myeloma care},
	journal = {Leukemia},
	volume = {28},
	year = {2014},
	note = {Cited By :43Export Date: 21 February 2017},
	month = {2014},
	pages = {981 - 992},
	abstract = {Recent developments have led to remarkable improvements in the assessment and treatment of patients with multiple myeloma (MM). New technologies have become available to precisely evaluate the biology and extent of the disease, including information about cytogenetics and genetic abnormalities, extramedullary manifestations and minimal residual disease. New, more effective drugs have been introduced into clinical practice, which enable clinicians to significantly improve the outcome of patients but also pose new challenges for the prevention and management of their specific side effects. Given these various new options and challenges, it is important to identify the minimal requirements for diagnosis and treatment of patients, as access to the most sophisticated advances may vary depending on local circumstances. Here, we propose the minimal requirements and possible options for diagnosis, monitoring and treatment of patients with multiple myeloma. {\textcopyright} 2014 Macmillan Publishers Limited. All rights reserved.},
	keywords = {global perspective, management of myeloma-related side effects, myeloma care},
	url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84899915546\&doi=10.1038\%2fleu.2013.293\&partnerID=40\&md5=62f92c2c5704122d2ec985972dad5036},
	author = {Ludwig, H. and Miguel, J.S. and Dimopoulos, M.A. and Palumbo, A. and Garcia Sanz, R. and Powles, R. and Lentzsch, S. and Ming Chen, W. and Hou, J. and Jurczyszyn, A. and Romeril, K. and Hajek, R. and Terpos, E. and Shimizu, K. and Joshua, D. and Hungria, V. and Rodriguez Morales, A. and Ben-Yehuda, D. and Sondergeld, P. and Zamagni, E. and Durie, B.}
}
